539 results match your criteria: "Rheumatology Center[Affiliation]"
Mod Rheumatol
December 2024
Department of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University.
Objective: To assess the prevalence and outcomes among regimens of glucocorticoid tapering for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in real-world practice.
Methods: We retrospectively examined the Japan Collaborative Registry of ANCA-associated Vasculitis (J-CANVAS) registry, and evaluated the prevalence of glucocorticoid tapering regimens in the PEXIVAS trial. In patients with newly diagnosed MPA and GPA, we compared outcomes among standard and reduced pace regimens.
BMC Rheumatol
December 2024
Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Background: This study aimed to compare the efficacy and safety of baricitinib in patients with rheumatoid arthritis (RA) receiving different doses based on renal function.
Methods: We conducted a retrospective study within the JAK Study Group, involving 23 facilities in Fukuoka Prefecture, examining patients treated with baricitinib for RA. Patients were categorized into two dose groups: 4 mg with normal/mild renal dysfunction and 2 mg with moderate renal dysfunction.
Med J Islam Repub Iran
August 2024
Department of Clinical Disciplines, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Background: High titers of specific antibodies to cyclic citrulline peptide (ACCP) are often present in the serum of patients with rheumatoid arthritis (RA) and, together with rheumatoid factor (RF), are a diagnostic marker of RA. Brucellosis is a zoonotic infection in which osteoarticular involvement occurs in 10-85% of patients. RF in brucellosis patients is significantly higher than in healthy people.
View Article and Find Full Text PDFRheumatology (Oxford)
December 2024
Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Monash University, Clayton, Victoria, Australia.
Objective: High disease activity status (HDAS) in patients with systemic lupus erythematosus (SLE) is associated with adverse long-term outcomes. We examined the frequency of lupus low disease activity state (LLDAS) and remission (REM) attainment in HDAS patients and whether their attainment was associated with improved patient outcomes.
Methods: Demographic, clinical and outcomes data, collected prospectively from a multinational cohort between 2013 and 2020, were analysed.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Acute Rheumatology Center, Bad Kreuznach, Germany.
Objectives: To evaluate the combination of novel colour Doppler ultrasound (CDUS), greyscale ultrasound (GSUS), and oscillometric indices of macroangiopathy in patients with idiopathic inflammatory myopathies (IIM). Second, to explore the associations between these imaging markers and both patient-related and disease-related characteristics, as well as traditional cardiovascular (CV) risk factors.
Methods: We conducted CDUS to evaluate arterial compliance markers, specifically the resistance (RI) and pulsatility (PI) indices, both in the common (CCA) and internal carotid arteries (ICA) of patients with IIM and healthy controls.
Ther Adv Musculoskelet Dis
December 2024
Rheumatology Unit, ERN ReCONNET Center, Meyer Children's Hospital IRCCS, Florence, Italy.
Background: Behçet disease (BD) is a rare disease in childhood and its uveitis may lead to blindness if not properly treated.
Objectives: We aim to describe a cohort of paediatric BD patients with uveitis.
Design: This is a multicentric retrospective study.
Background: The General Medicine In-Training Examination (GM-ITE) tests clinical knowledge in a 2-year postgraduate residency program in Japan. In the academic year 2021, as a domain of medical safety, the GM-ITE included questions regarding the diagnosis from medical history and physical findings through video viewing and the skills in presenting a case. Examinees watched a video or audio recording of a patient examination and provided free-text responses.
View Article and Find Full Text PDFArthritis Rheumatol
December 2024
Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, USA.
Sensors (Basel)
November 2024
Department of Rheumatology, Suwa Central Hospital, Nagano 391-0011, Japan.
In 2020, 20% of patients with COVID-19 developed severe complications, including life-threatening pneumonia with systemic inflammatory response syndrome (SIRS). We developed a preliminary SIRS monitor that does not require blood sampling, is noninvasive, and can collect data 24 h per day. The proposed monitor comprises a piezoelectric respiratory sensor located beneath the patient's mattress and a fingertip pulse sensor that determines ultra-high accuracy respiratory rate (mode of a 40-min frequency distribution of respiratory rates (M40FD-RR)).
View Article and Find Full Text PDFBest Pract Res Clin Rheumatol
November 2024
Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan; Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
Joint Bone Spine
November 2024
Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Siena, Italy. Electronic address:
Mod Rheumatol
November 2024
Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan.
Objectives: We studied the current state and factors associated with the acceptance or hesitancy of booster doses of the coronavirus disease 2019 (COVID-19) vaccine among patients with autoimmune and rheumatic diseases (ARDs) in Japan.
Methods: A single-center cross-sectional survey was conducted among outpatients with ARDs who visited the Immuno-Rheumatology Center at St. Luke's International Hospital from 1 October to 30 November in 2023.
J Rheumatol
November 2024
Luca Cantarini, Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Siena, Italy; Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center] Siena, Italy.
Objective: To evaluate the cardiac involvement in patients with Still's disease with a focus on myocarditis included in the multicenter AIDA (AutoInflammatory Disease Alliance) network Still's disease registry. To exploit the predictive factors for myocarditis in deriving a clinical risk patient profile for this severe manifestation.
Methods: A multicenter observational study was built up assessing consecutive patients with Still's disease characterized by the cardiac involvement among those included in the AIDA Network Still's Disease Registry.
J Rheumatol
December 2024
H. Tamaki, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
Int J Rheum Dis
November 2024
Department of Rheumatology, Kochi Memorial Hospital, Kochi, Japan.
Arch Rheumatol
September 2024
Immuno Rheumatology Center St. Luke's International Hospital, Tokyo, Japan.
Ann Rheum Dis
October 2024
Rheumatology Center, Toulouse University Hospital, Toulouse, France.
Pediatr Rheumatol Online J
October 2024
German Center for Pediatric Rheumatology, Garmisch-Partenkirchen, Germany.
Background: Methotrexate (MTX) intolerance in juvenile idiopathic arthritis (JIA) frequently leads to discontinuation due to anticipatory and associative gastrointestinal symptoms. Eye Movement Desensitization and Reprocessing (EMDR) has successfully been used in MTX intolerance, with lasting effects but frequently diminishing efficacy over time. BLAST (bi-lateral alternating stimulation tactile) wristbands utilize a similar process to EMDR.
View Article and Find Full Text PDFRMD Open
September 2024
Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, Netherlands
Laeknabladid
October 2024
Consultant rheumatologist, Rheumatology center and Landspítali. Chairman of the Reykjavík Medical Association.
Arthritis Res Ther
September 2024
Department of Rheumatology, Acute Rheumatology Center Rhineland-Palatinate, Kaiser-Wilhelm-Str. 9-11, 55543, Bad Kreuznach, Germany.
Objectives: The aims of this study were to suggest patient-adjusted optical spectral transmission (OST) cut-off values for the first time and to develop clinical models that predict the probability of an early rheumatoid arthritis (RA) diagnosis based on OST findings and the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria as a reference standard.
Methods: OST examinations were performed in newly diagnosed RA patients and healthy controls by the HandScan device. Moreover, RA patients underwent a full clinical [tender/swollen joint counts (TJC/SJC), disease activity score-28 (DAS28)] and laboratory evaluation.
Rheumatology (Oxford)
September 2024
Scleroderma Clinic, UOC Clinica Reumatologica, ASST Gaetano Pini-CTO Milano, Milan, Italy.
Reumatismo
September 2024
Department of Clinical and Biological Sciences, Academic Rheumatology Center, University of Turin, Ospedale Mauriziano, Turin.
Objective: The journey to a diagnosis of spondyloarthritis (SpA) can be difficult for women, who often experience delays in receiving the correct diagnosis as their symptoms are frequently misinterpreted due to other conditions like osteoarthritis, fibromyalgia, or other psychosomatic disorders. The purpose of this article is to examine the challenges in the diagnosis of SpA in women and the possible role of musculoskeletal ultrasound in early diagnosis and in avoiding misdiagnosis.
Methods: We have performed a narrative review of the currently available literature on the subject.
Mod Rheumatol Case Rep
September 2024
Nephrology and Rheumatology center, and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, 105-8470, Japan.
Expert Opin Biol Ther
October 2024
Inflammation & Immunology Emerging Markets, Pfizer, Makati, Philippines.
Background: This study evaluated physicians' and patients' beliefs about biosimilars in Hong Kong, India, Pakistan, Singapore, Taiwan, and Thailand.
Research Design And Methods: An online survey administered to physicians (dermatologists, = 119; gastroenterologists, = 148; rheumatologists, = 161) between 22 October 2021 and 7 January 2022, and patients ( = 90) with rheumatic or inflammatory bowel disease between 25 October 2021 and 12 April 2022.
Results: Most (68%) physicians reported having a strong knowledge about biosimilars, yet 49% indicated that biosimilars are readily available to them.